This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk09: Thank you for your patience. Please remain connected. Your call will begin shortly. And all, once again, we thank you for your patience. Please remain on the line. Your call will begin in approximately one minute. Thank you. Greetings all, and welcome to the Elladon Pharmaceuticals Report's first quarter 2021 financial results. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question and answer session. At that time, if you have a question, please press the one followed by the four on your telephone. Should you require operator assistance at any time, please press star zero. As a reminder, this call is being recorded today, Thursday, May 13th, 2021. I'd now like to turn the call over to John Kuwahara, Senior VP of Finance. Please go ahead.
spk07: Good afternoon, and thank you all for joining Elladon Pharmaceuticals' first quarter 2021 financial results conference call. Joining me today are three members of our leadership team, David Alexander-Grove, Chief Executive Officer, Steve Perrin, President and Chief Scientific Officer, and Paul Little, Chief Financial Officer. Earlier today, Eladon issued a press release announcing financial results for the first quarter ended March 31, 2021. You may access the release under the Investors tab on our company website, eladon.com. Before we begin, I would like to remind everyone that statements made during this conference call relating to Alidon's expected future performance, future business prospects, or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from these forecasts, due to the impact of many factors beyond the control of Eladon. Eladon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in Eladon's reports, followed with the Securities and Exchange Commission. It is now my pleasure to pass the call to our CEO, Dr. David Alexander Groh. DA?
spk02: Thank you, John, and good afternoon, everyone. We made good progress during the first quarter, advancing both our company and our lead molecule, AT1501. I'm excited by the promise offered to us by AT1501 as a potential therapeutic for organ or cellular transplantation, ALS, and serious immunological diseases where patients face limited treatment options. Steve will go into details. around AT1501 program updates, but at a high level in the first quarter of this year, we continue to enroll patients into and remain on track for our ongoing ALS Phase II study. We reopened our Canadian site for our Phase II islet cell transplantation study for the treatment of type 1 diabetes, and we received FDA feedback and updated our development strategy in renal transplantation. Operationally, we completed our evolution into Elladon Pharmaceuticals from Novus Therapeutics. We also bolstered our senior leadership team to help us execute on our plans and achieve our short and long-term goals. Regarding the team, I'm extremely pleased to introduce four new executives, Paul Little as Chief Financial Officer, Jeff Bornstein as Chief Medical Officer, David Hovland as Chief Regulatory Officer, and Brian Smith as General Counsel, Corporate Secretary, and Chief Compliance Officer. With them on board, I'm thrilled that we've built out a top-tier leadership team that I believe positions us to achieve success for the benefit of patients and shareholders alike. I will now turn the call over to Steve Perrin, our President and Chief Scientific Officer, to discuss our clinical programs, after which Paul Little will provide a financial update. Steve, please go ahead.
spk04: Thank you, DA. For those of you that are new to Eladon's story, I'll start by giving a brief overview of our lead asset, AT1501, an IgG1 anti-CD40 ligand antibody lacking FC effector function. Physiologically, the interaction of CD40 ligand and CD40 results in clonal expansion, antibody production, and secretion of pro-inflammatory cytokines that amplify an immune response. The CD40-CD40 ligand pathway is an attractive drug target because the engagement of these receptors plays a pivotal role in immune system activation by mediating both antibody and cellular immune responses. We are focusing our efforts on the development of an antagonist antibody targeting the ligand rather than the receptor since targeting the ligand has been shown to be more efficacious in preclinical models of autoimmunity as well as in the prevention of acute and long-term allograft transplant rejection. There may be three different biological mechanisms that benefit targeting anti-CD40 ligand over targeting anti-CD40 receptor. The ligand is expressed on fewer cell types with expression generally restricted to platelets, endothelial cells, and activated lymphocytes, whereas the receptor is more broadly expressed on antigen-presenting cells, including monocytes, macrophages, dendritic cells, and specialized antigen-presenting cells. Second, targeting both the receptor and the ligand inhibits B-cell activation and class switching, as well as inhibiting the pro-inflammatory polarization of CD4-positive helper T cells. However, blocking CD40 ligand also inhibits other integrin receptors, including CD11 receptors on antigen-presenting cells, thus blocking the pro-inflammatory polarization of CD8-positive cytotoxic T cells as well. And third, blocking the ligand also polarizes CD4-positive lymphocytes to FOXP3-positive Tregs, thus potentially creating a more telegenic environment. Our current development strategy is to target four indications, which I'll discuss in order of clinical development. First, amyotrophic lateral sclerosis, or ALS, where we currently have a Phase II trial enrolling. Second, islet cell transplantation as a potential functional cure for people living with type 1 diabetes, where we currently have an active clinical site in Canada. Third, prevention of kidney allograft transplant rejection, where we have received guidance from the FDA on the path forward in the United States and are in parallel exploring a renal transplant study, XUS. And fourth, autoimmune nephritis, where we are finalizing indication selection and plan to communicate our strategy next quarter. I'll now go into more detail regarding each of these indications. In ALS, Elidon initiated a phase two safety, tolerability, and biomarker study in October of 2020. The trial was a 12-week open-label dose-escalating study with four doses of AT-1501. Currently, the study is enrolling at 12 sites in the United States and Canada. Our enrollment continues to be on track and we expect to read out top-line data in the first half of 2022. We will assess two primary categories of biomarker endpoints with each subject serving as their own control by comparing changes from baseline. In the first category, we will assess biomarkers of CD40 ligand target engagement. Mechanistically blocking CD40 ligand has profound effects on B-cell maturation, antibody production, and antibody class switching. We anticipate that we will be able to assess CD40 logger and tiger engagement by AT1501 with markers of B cell function, such as CXEL13. The second category of biomarkers are changes in pro-inflammatory chemokines and cytokines upregulated in people living with ALS. There is a long history of ALS data describing increases of pro-inflammatory signals in circulation, including TNF-alpha, MCP1, IL-6, and enraged. We anticipate blocking of CD40 ligand will result in an overall decrease of ALS-related pro-inflammatory markers in circulation. Finally, we will also assess the other exploratory endpoints, including changes in ALS functional rating scale, or ALS-FRS, respiratory function, as well as the levels of neurofilament light chain in circulation, since recent publications have shown a correlation between levels of neurofilament light chain and the rate of disease progression in ALS. In diabetes, we are focusing on people living with a brutal phase of type 1 diabetes who are on chronic treatment with exogenous insulin and experience severe swings in blood glucose levels, hypoglycemic unawareness, and associated comorbidities. Clinical trials conducted by the Clinical Islet Transplantation Consortium, as well as islet cell transplants in other countries, have demonstrated that islet cell transplant in patients with difficult neural type 1 diabetes may help maintain glycemic balance, reinstate metabolic control, and in some cases, even eliminate the need for exogenous insulin. However, the current use of calcineurin inhibitors, or CNIs, necessary for the prevention of islet cell transplant rejection poses two issues. First, CNIs are toxic towards transplanted islets, potentially resulting in significant islet cell loss post-transplant and may lead to the requirement for multiple islet cell transplants. Indeed, in published trials, islet cell transplant recipients typically require multiple transplants with a need for a second transplant, often apparent within approximately 90 days after the first transplant. Beyond islet cell toxicity, CNIs have a long list of associated toxicities, including nephrotoxicity, cardiotoxicity, tremor, and hair loss. As a result, we believe that replacing CNIs with AT1501 may improve islet cell survival and clinical outcomes associated with islet cell transplant, thus potentially allowing for islet cell transplant to become a viable treatment option and even a potential functional cure for persons living with brittle type 1 diabetes. In collaboration with Norma Kenyon at the University of Miami, We have generated preclinical data in a non-human primate model of islet cell transplant demonstrating that AT1501 in combination with other immunomodulators or as monotherapy may have the ability to prevent acute and long-term rejection of transplanted islets. We currently have an active clinical site in Alberta, Canada seeking to enroll a single open arm label study. Primary endpoints include safety and tolerability, glucose control, insulin independence, reduction in HbA1c, and graft survival and function. We will also be assessing hypoglycemic unawareness events, as well as renal function. Although Alberta has been significantly impacted by COVID and the virus has complicated travel in Canada, we are still targeting to enroll a first patient this quarter and generate interim data in Iloxil transplant in the first half of 2022. With regards to data, we also look forward to having presentations and posters at the American Transplant Conference in June, where we plan to present data from our Phase I clinical study of AT50-01, as well as preclinical data, including characterization of AT50-01 and in vitro assays in nonhuman primate studies of AT50-01 and the prevention of islet cell transplantation rejection. Moving on to renal transplantation. I'd like to address the announcement we made on April 26th, updating our development strategy for AT50-01 in renal transplantation following our ongoing discussions with the FDA. Recall as background that we've already studied AT50-01 and demonstrated a good safety profile in over 60 non-human primates, including a model of islet cell transplantation where the molecule also showed preclinical efficacy. Moreover, multiple historical anti-CD40 ligand molecules similar to AT5001, have demonstrated preclinical safety and efficacy in hundreds of non-human primates, including specifically in non-human primate models of renal transplantation. Nevertheless, as part of our normal course of discussions to start the Phase II trial for kidney transplantation, the FDA requested that we first provide AT5001 drug-specific renal transplant data in non-human primates prior to initiating a Phase II trial in the US. To meet the agency's request, we plan to initiate a preclinical study of 18-1501 and a non-human primate model of renal transplantation, which we expect to complete in late 2022. Although we cannot fully predict what regulators and other jurisdictions will now require, we are also exploring the ability to conduct a renal transplantation clinical trial outside the U.S. in parallel to this new non-human primate study. We will provide updates on this potential clinical trial and its design as we have discussions with and receive feedback from international regulatory agencies. Of note, the FDA feedback on renal transplantation does not impact our other ongoing development programs in either the U.S. or Canada. There have been no significant new drug-related safety signals with AT5001, and this new FDA request was not due to any specific event or data from our ongoing trials of AT5001. In autoimmunity, we are focusing on autoimmune nephritis, which are autoimmune diseases of the kidney. There was a long history of preclinical and clinical data demonstrating that blocking CD40 ligand signaling ameliorates disease progression, modifies biomarkers of disease, and improves renal function in diseases such as focal segmental glomerulosclerosis, lupus nephritis, and IgA nephropathy. Moreover, a soluble CD40 ligand often correlates with disease flares in autoimmune diseases such as these. We look forward to providing more details on our development plans in autoimmune nephritis next quarter. With that, I'll turn the call over to Paul for a financial update.
spk03: Thank you, Steve. In addition to the financial results summarized in our press release, you can find additional information in our Form 10-Q, which we will file later today. The company reported a net loss of 8.5 million, or 57 cents per share, for the three months ended March 31st, 2021, compared to a net loss of 8.2 million, or $8.52 per share, for the same period in 2020. Research and development expenses were 5.6 million for the three months ended March 31st, 2021, compared to 1.6 million for the same period in 2020. The increase in R&D costs was primarily due to spin related to the production of clinical trial materials and other CNC activities as we advance our AT1501 program. General administrative expenses were $3.3 million for the three months ended March 31st, 2021, compared to $1.7 million for the same period in 2020. The company had approximately $108.6 million in cash and cash equivalents as of March 31st, 2021, compared to $114.2 million in cash and cash equivalents as of December 31, 2020. We expect our financial resources to be sufficient to fund operations as currently planned well into 2023. With that financial update, let me turn the call back over to DA to highlight some of our key upcoming milestones for 2021.
spk02: Thank you, Paul. In the early part of this year, we became Elladon Pharmaceuticals, and both continued to make progress advancing AT1501 and building out our team. During the second quarter, we expect to initiate a phase two trial in islet cell transplantation in type 1 diabetes, and we will be presenting AT1501 data, including non-human primate data in a type 1 diabetes model at the American Society of Transplantation annual meeting in June. Moving forward, We'll continue our efforts to advance a renal transplantation program by initiating a study in a non-human primate model while exploring a parallel track that would involve a clinical trial outside the U.S. Lastly, we'll also continue to work on our preparations in autoimmune nephritis, where we expect to launch a trial later this year. With our world-class team and strong cash position, we believe that we are well positioned to deliver on these important milestones as we develop Eladon into a leading targeted immunology company focused on the CD40-CD40 ligand pathway. With that, I will now ask the operator to begin our Q&A session. Operator?
spk09: Certainly, and thank you very much. If you would like to register a question, please press the one followed by the four on your telephone. You will hear a three-tone prompt to acknowledge your request. If your question has been answered and you would like to withdraw your registration, please press the one followed by the three. Once again, to register a question, it is 1-4 on your telephone keypad. Our first question comes from Alicia Young with Cantor. Your line is open.
spk06: Hi. Thanks for taking the call. This is Lee Ong for Alicia. I'm just kind of curious why you think the FDA wanted specific information related to 1501 when given that there's already data out there from the competitors?
spk02: So, I think the FDA was focused on being able to see drug specific and organ-specific data. So as you know, we have done, as we discussed on this call, non-human primate studies looking at transplantation, but with islet cells. And here in transplantation, we're in a unique situation where it becomes hard to separate safety and efficacy data, since one needs efficacy in order to be able to protect the organ. So what the FDA was looking for was to have specific information on AT1501 in renal transplantation in order to make sure that, to give comfort that there would be not only safety but efficacy in this particular type of transplantation.
spk06: Okay, got it.
spk02: And that really has to do. There's, as you know, each organ is very valuable here, and so there's quite a high bar with transplantation.
spk06: Okay. Just to follow up, can you just maybe talk a little bit more about your potential plans to run an XUS study for 1501 in renal transplant just to, you know, sort of generate some proof of concept data here?
spk02: Exactly. So these are still early days in these discussions. As you know, we just received the feedback from the agency recently. But the goal would be to do a smaller trial than what we had initially anticipated, but one that could be done internationally. And to your point, would allow us to begin to be able to show data in terms of both safety and efficacy in renal transplantation in humans.
spk06: Okay. Got it. Thank you.
spk00: Great. Thank you.
spk09: And our next question comes from Rami Khatkuva with LifeSci Capital. Your line is open.
spk08: Hey, guys. Thanks for taking my question. Just a quick one for me, but based on preclinical IT data, that ITT data that you presented Do you guys envision utilizing a monotherapy arm in the upcoming Phase II trial, or will you test 1501 in combo with standard of care?
spk02: Just to clarify, are you talking about the renal trial, the human islet cell transplant trial, or the non-human primate renal trial?
spk08: Sorry, this would be for the human islet cell transplantation trial.
spk02: Let me turn that over to Steve to talk about that trial.
spk04: Yeah, no, currently the human islet cell transplant trial is not a monotherapy trial. It's a trial where we're trying to really achieve getting rid of calcineurin inhibitors due to the associated toxicities that we described. We really feel that in the absence of CNIs based on our preclinical data and historical preclinical data that we'll have much better islet cell survival, much better islet cell function. and hopefully reduce the number of transplants required to get people a large enough islet cell mass to really impact insulin production. So it's not a monotherapy trial. It's a trial with induction therapy plus maintenance therapy.
spk08: Got it. Thank you very much. Thank you.
spk09: Thanks, Remy. Our next question comes from Thomas Smith with SVB Lyric. Your line is open.
spk10: Hey, guys. Good afternoon. Thanks for taking the questions. First, just on the updated plan and renal transplant, can you provide a little more color on the plans for running the additional non-human primate study? I know you've laid out some initial timelines, but just a sense of, I guess, size and scope and specifically what you're looking for.
spk04: Yeah, so we're still in discussions with the agency about the design. Obviously, we're trying to be sensitive for the utilization of non-human primates in these types of experiments, but understand, you know, the ability to generate that type of data. I mean, the guidance from the agency, they want to show our ability to prevent transplant rejection. So that was probably the most important requirement as we think about our design with them. But we're still in a dialogue on what that design needs to look like. Yeah.
spk02: most likely include monotherapy in order to be able to show the effect specifically of our antibody.
spk10: Okay, great. And then a follow-up question just in terms of the ALS study enrollment. You know, as we're starting to see some improvement in COVID-19 infection rates, maybe if you could just talk a little bit Enrollment trends, are you guys seeing any meaningful changes in terms of patient enrollment or cadence that gives you a little bit more confidence in the first half 22 timeline for data?
spk02: So in terms of the ALS trial, as we mentioned, we're on track. Overall, we've been on track for pretty much the whole the whole time since we've launched the trial. We did see some slowdowns that were associated with the various COVID peaks here in the United States, but maybe because we're in enough sites and the sites are distributed across the United States and Canada, it did not have a meaningful impact in terms of recruitment and enrollment. So with regards to that one trial, we continue to see good interest as we've seen, but at least that specific trial has been so far quite independent of what's been happening with COVID.
spk10: Okay, great. I appreciate the color. Thanks, Seth.
spk09: And as a brief reminder to all to register for a question, It is 1-4 on your telephone keypad. Next question comes from Matt Kaplan with Leidenberg-Solomon. Your line is open.
spk01: Hi. Good evening, guys. Thanks for taking the question. Just wanted to follow up a little bit on the islet cell transplant trial. Sounds like you're about to have your first patient enrolled in that near term. How should we think about kind of the rollout of data from that study? Is it going to be as you reach a certain cohort number, or will you announce data as you get kind of towards the completion of the study?
spk02: Great. Thank you very much, Matt. Let me turn that over to Steve.
spk04: Yeah, it's a great question, Matt. I mean, obviously, we want a cohort of patients to be able to determine readouts in the study. So, we're enthusiastic that the site is active and, you know, we're looking forward to our first patient coming in. But, you know, we need three or four subjects worth of data to really understand the outcomes that we're looking at in the study, which is islet cell function, metabolic control, glycemic awareness, So I think we're still on track to be able to acquire that data for late next year, but we're not going to be announcing data on a subject-by-subject basis.
spk02: Yeah, so we'll announce the data on the first subset in the first half of next year, and then we would expect to have the full number of patients enrolled and to get that data, the full top-line data in the second half.
spk01: Okay. That's very helpful. Thank you. And then a second question. You mentioned some upcoming... presentations at the American Society of Transplantation. Can you give us a little bit more color in terms of what to look for there as you announce those data sets in June?
spk04: Yeah, sure. There's four presentations that's going to happen at the Transplant Congress. There's two posters and two oral presentations. One of the posters is focusing on the historical design of AT1501. and its characterization primarily in in vitro studies with receptor binding, FC effector function, and lack of platelet activation. The second poster is focused on the non-human primate work that we did initially with AT1501, so talking about the pharmacokinetics in non-human primates, as well as reviewing data from our two toxicity studies that we did in non-human primates at 12 weeks, study, as well as a subsequent 26-week study. The two oral presentations, one of them is focusing on a presentation of our phase one data of AT50-01, primarily in healthy volunteers, but we did have a cohort of ALS patients in that study. And again, focusing on safety readouts, pharmacokinetics, ADA responses, as well as we did do an immune challenge showing functional activity of the antibody in that study. And then the last presentation will be presented actually by Norma Kenyon, our collaborator at UMiami, who has worked with AT5001 in her non-human primate islet cell model. And she'll be presenting data on AT5001 in combinations with other traditional immune modulatory drugs that are used in the context of transplant rejection, as well as presenting data with several doses of AT5001, either as a monotherapy presenting data on the ability of AT51 to prevent acute and long-term islet cell transplant rejection.
spk01: Great. Thanks a lot for the added color, Steve.
spk04: You're welcome.
spk09: And I'll just brief reminder to register a question. It's 1-4 on your phone. Next question comes from Vernon Bernadito. Bernardino, my apologies, from HC Wainwright. Your line is open.
spk05: Thanks for taking my question. No worries. You might get my evil twin if you say that, though. Just to follow up on Matt's question, Steve, can you describe a little bit what the immune challenge is and how it's done?
spk04: Yeah, there's a couple of different ways to do immune challenges. What we do, typically it's done with any type of a foreign antigen. So tetanus toxin is one that's not uncommon. KLH is another one that's very common. That's the one that we used. It's a protein that's derived from shellfish. And so you can imagine, and we try to avoid people with this type of an experiment that actually have shellfish allergies. But if you take a foreign antigen like from shellfish and inject it subcutaneously, under the skin, it would generate a very acute hypersensitivity reaction because your body has never seen that protein before. So the way these experiments are typically done, and we did it a little bit different, typically what one would do is enroll your subjects into the study, and probably three to seven days before you do that foreign protein challenge, you would start treating them with your immune modulatory or immunosuppressive drug to start tampering down their immune system, and then you come in and do your sub-Q challenge to see if you can block the body's immune system from recognizing that foreign antigen. What we did in our phase one study was actually quite more aggressive than that. We actually injected the KLH sub-Q at the exact same time that we did our IV infusion of AT1501, and yet we demonstrated the ability to completely block the immune system's recognition of that foreign antigen in two of three subjects. And we did get a pretty good attenuation even in that third subject. So under a very difficult challenge, it was the first data to show we had functional activity of AT5001 in humans.
spk05: And so you'll do the same with the current ALS study that is on the same day?
spk04: So in the ALS study, we're not planning on doing any KLH. challenges in that phase two study in ALS.
spk05: Okay. And would that data for the immune challenge serve as the result you would keep in mind as far as the results concern across the board as far as the different studies, ALS, renal, and ILIT?
spk04: I mean, the goal of the KLH study and the Phase 1 study was really to just show the first signs of functional activity for AT5001 in humans. In our subsequent studies, we're more focused on disease-specific biomarkers to show functional activity. As I described in our ALS study, there's a couple of different biomarker components to that study, one of them being the ability to look at AT5001 changing B cell function So as I described, when you block the CD40 ligand pathway, it has a dramatic impact on B-cell maturation, antibody production, class switching. And one of the ways you can measure that is markers of B-cell function, and one of them is CXCL13. Another way to measure whether AT1501 is having effects in ALS is to look at those pro-inflammatory markers that have been described in multiple studies that are elevated in people with ALS compared to healthy controls. And if an AT51 modulates the immune system, it should have an impact on those pro-inflammatory markers.
spk05: Perfect. Looking forward to the ALS data at the phase one data at transplantation and continued progress with the ALS and renal studies. Thank you for taking my question. Thank you. Thanks, Vernon.
spk09: And there are no further questions at present time. Please continue with your presentation or closing remarks.
spk02: Thank you again to everyone for joining us on the call. We are pleased you could join us today to hear our progress during the first quarter, and we look forward to keeping you updated on our programs.
spk09: And all that does conclude the call for today. We thank you very much for your participation. And as you please disconnect your line.
Disclaimer